| Study | Reason for exclusion |
|---|---|
| Acharya 2004 | Not a RCT. |
| Anonymous 1995 | Wrong type of participants were included; did not assess non‐infectious posterior uveitis, intermediate uveitis, or panuveitis. |
| Ansari 2010 | Not a RCT. |
| Arcinue 2013 | Not a RCT. |
| Bollinger 2009 | Wrong type of participants were included; did not assess non‐infectious posterior uveitis, intermediate uveitis, or panuveitis. |
| Callanan 2008a | Did not compare fluocinolone or dexamethasone implant with standard‐of‐therapy. The study compared 0.59‐mg FA intravitreal implant with 2.1‐mg FA intravitreal implant. |
| Campochiaro 2013 | Wrong type of participants were included; did not assess non‐infectious posterior uveitis, intermediate uveitis, or panuveitis. |
| Cano‐Parra 2006 | Not a RCT. |
| CTRI/2014/07/004726 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐therapy. The study compared FA intravitreal implant with sham injection. |
| CTRI/2014/12/005337 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐therapy. The study compared FA intravitreal implant with sham injection. |
| Eng 2007 | Wrong type of participants were included; did not assess non‐infectious posterior uveitis, intermediate uveitis, or panuveitis. |
| Ermakova 2003 | Not a RCT. |
| Galor 2007 | Not a RCT. |
| Garg 2006 | Not a RCT. |
| Goldstein 2007 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐therapy. The study compared 0.59‐mg FA intravitreal implant with 2.1‐mg FA intravitreal implant. |
| Ibrahim 2009 | Not a RCT. |
| Jaffe 2000a | Not a RCT. |
| Jaffe 2000b | Not a RCT. |
| Jaffe 2005a | Did not compare fluocinolone or dexamethasone implant with standard‐of‐therapy. The study compared 0.59‐mg FA intravitreal implant with 2.1‐mg FA intravitreal implant. |
| Jaffe 2005b | Not a RCT. |
| Jaffe 2006a | Did not compare fluocinolone or dexamethasone implant with standard‐of‐therapy. The study compared 0.59‐mg FA intravitreal implant with 2.1‐mg FA intravitreal implant. |
| Jaffe 2006b | Did not compare fluocinolone or dexamethasone implant with standard‐of‐therapy.The study compared 0.59‐mg FA intravitreal implant with 2.1‐mg FA intravitreal implant. |
| Kim 2011 | Not a RCT. |
| Kuppermann 2007 | Wrong type of participants were included; did not assess non‐infectious posterior uveitis, intermediate uveitis, or panuveitis. |
| Lowder 2011a | Did not compare fluocinolone or dexamethasone implant with standard‐of‐therapy. Participants were randomized to either a sham procedure or treatment with the 0.7‐mg or 0.35‐mg DEX implant. |
| Mercante 2007 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐therapy. The study compared 0.59‐mg FA intravitreal implant with 2.1‐mg FA intravitreal implant. |
| Muller 2004 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐care therapy. The study compared 0.59‐mg FA intravitreal implant with 2.1‐mg FA intravitreal implant. |
| Mustakallio 1973 | Wrong type of participants were included; did not assess non‐infectious posterior uveitis, intermediate uveitis, or panuveitis. |
| Naik 2013 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐care therapy. The study compared dexamethasone intravitreal implant with sham injection. |
| NCT01694186 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐therapy.The study compared FA intravitreal implant with sham injection. |
| NCT02309385 | Did not have at least six months of follow‐up after treatment. |
| NCT02482129 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐care therapy. The study compared LME636 60 mg/mL ophthalmic solution with dexamethasone 0.1% ophthalmic solution. |
| NCT02517619 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐care therapy. The study compared dexamethasone ophthalmic solution (40 mg/mL) with prednisolone acetate ophthalmic solution (1%). |
| Neger 1996 | Wrong type of participants were included; did not assess non‐infectious posterior uveitis, intermediate uveitis, or panuveitis. |
| Novack 2008 | Not a RCT. |
| Ram 2013 | Wrong type of participants were included; did not assess non‐infectious posterior uveitis, intermediate uveitis, or panuveitis. |
| Sangwan 2007 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐care therapy. The study compared 0.59‐mg FA intravitreal implant with 2.1‐mg FA intravitreal implant. |
| Saraiya 2011 | Not a RCT. |
| Sheppard 2012 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐care therapy. The study compared 0.59‐mg FA intravitreal implant with 2.1‐mg FA intravitreal implant. |
| Taylor 2012 | Not a RCT. |
| Viola 2009 | Not a RCT. |
| Wen 1991 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐therapy. The study compared Chinese traditional dialectic therapy combined with eastern medicine versus western medicine. |
| Williams 2004 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐care therapy and included participants with either uveitis or Irvine‐Gass syndrome. |
| Williams 2009 | Did not compare fluocinolone or dexamethasone implant with standard‐of‐care therapy. Participants were randomized to 350‐ɥg dexamethasone or 700‐ɥg dexamethasone or observation. |
| Yeh 2008 | Not a RCT. |
FA: fluocinolone acetonide mg: milligram RCT: randomized controlled trial